Takeda Korea appoints Kwang-gyu Park as new General Manager

Has extensive experience in the field, from Specialty Care to Oncology

Has demonstrated leadership at global pharmaceutical companies such as BMS, MSD, and Gilead

Takeda aims to strengthen patient-centric solutions and access to innovative treatments through appointment

Kwang-kyu Park, new General Manager of Takeda Pharmaceuticals Korea

Takeda Pharmaceuticals Korea announced on the 18th that it has appointed Kwang-kyu Park as its new General Manager as of March 17, 2025.

 

Park is a pharmaceutical industry expert with more than 20 years of experience in the industry and strong expertise and leadership in Specialty Care and Oncology (hematologic malignancies and immunotherapy).

 

Park graduated from Kyung Hee University with a degree in Pharmacy and earned an MBA from the Graduate School of Business at Seoul National University.

 

Since then, he has demonstrated leadership in global companies such as BMS Korea, AstraZeneca Korea, and MSD Korea, leading the introduction of new drugs, organizational innovation, and stakeholder collaboration.

 

Most recently, he served as the Senior Director of Gilead Sciences Korea’s Liver Disease Business Unit, playing a pivotal role in improving the treatment environment for liver diseases in Korea and realizing patient-centered medical innovation.

 

Park said, “Takeda Pharmaceuticals Korea has pursued continuous growth through patient-centered innovation amid the rapidly shifting medical environment.

 

We will continue to accelerate the introduction of innovative treatments and seek multi-faceted solutions to ensure that both the healthcare professionals and patients can have optimal treatment opportunities.” Park added, “We will strengthen cooperation with domestic bio and pharmaceutical companies to improve the treatment environment and contribute to the continuous development of the domestic pharmaceutical industry.” Mahender Nayak, Senior Vice President of Growth and Emerging Markets at Takeda Pharmaceuticals said, “We are very pleased to welcome Mr.

 

Park to Takeda Pharmaceuticals as we seek to advance our 6 innovative late-stage pipelines.

 

I expect His expertise, which includes his extensive business experience and strategic leadership, will serve a pivotal role in the continued success of Takeda Pharmaceuticals Korea.”